We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

BECKMAN COULTER, INC.

Beckman Coulter develops, manufactures and markets laboratory systems, reagents, centrifugation, lab automation, elec... read more Featured Products: More products

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Urine Test Predicts Heart Failure Patients' Risk of Kidney Injury

By LabMedica International staff writers
Posted on 11 Mar 2015
Print article
Image: The AU 480 automatic biochemical analyzer (Photo courtesy of Beckman Coulter).
Image: The AU 480 automatic biochemical analyzer (Photo courtesy of Beckman Coulter).
Levels of a protein in the urine may help clinicians predict which patients with acute heart failure are at increased risk of developing kidney injury during hospitalization.

Urinary angiotensinogen levels at the time of hospital admission predicted acute decompensated heart failure patients' risk of developing acute kidney injury with considerable accuracy and help clinicians predict patients' risk of being re-hospitalized or dying within one year.

Scientists at the Southern Medical University (Guangzhou, China) conducted a study in 436 patients with acute decompensated heart failure (ADHF) to validate a new marker, urinary angiotensinogen (uAGT), for predicting patients' risk of developing acute kidney disease (AKI). The primary objective was to test and validate the hypothesis that daily measures of uAGT during the first week of admission predict the development of AKI and one year prognosis in these patients. Spot urine and blood samples were collected immediately after admission before any in-hospital treatment and every 24 hours for the first seven days during hospitalization.

A sandwich enzyme-linked immunosorbent assay (ELISA) kit (Immuno-Biological Laboratories Co., Ltd.; Fujioka, Japan) was used for quantifying AGT in urine and plasma. Standard Western blot analyses with an affinity-purified goat polyclonal antibody against human AGT were used to quantify uAGT. To compare the predictive performance of uAGT and reported renal injury markers, urinary neutrophil gelatinase-associated lipocalin (NGAL) was measured with an ELISA kit (Antibody Shop; Utrecht Netherlands). Creatinine levels were measured using an automatic AU 480 biochemical analyzer (Beckman Coulter, Inc.; Brea, CA; USA).

The team demonstrated that uAGT levels at the time of hospital admission predicted AKI risk with considerable accuracy. The highest quartile of uAGT on admission was linked with a 50-times increased risk of AKI compared with the lowest quartile. Patients' uAGT level at the time of admission also helped clinicians predict patients' risk of being re-hospitalized or dying within one year.

Fan Fan Hou, MD, PhD, a senior author of the study, said, “Our results raise the possibility that by using sensitive and specific biomarkers such as uAGT, clinicians may be able to identify ADHF patients at high risk of developing AKI as early as on the first day of admission. If confirmed, uAGT levels on the first day of admission may improve clinicians' ability to assess ADHF patients' risk of developing AKI and to predict their one-year prognosis, which in turn would help clinicians to plan and initiate the most appropriate management strategies during hospitalization and post discharge.” The study was published on February 26, 2015, in the Journal of the American Society of Nephrology.

Related Links:

Southern Medical University
Immuno-Biological Laboratories Co., Ltd.
Beckman Coulter, Inc. 


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.